top of page

Turning back the clock on fibrosis

Small molecule inhibitors for reversal of fibrosis

First in class novel inhibitors targeting a central pathway in fibrosis and inflammation

Inosi is developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function.


Inosi’s technology is based on collaborative research from the founding team at Monash University, the Monash Biomedicine Discovery Institute, and the Monash Institute of Pharmaceutical Sciences.

IP Group helped spin-out the company and provided seed investment.

Our Partners


Fibrosis is a global problem with high unmet need


deaths linked to fibrosis


of the population have a fibrotic condition


drugs able to reverse fibrosis

bottom of page